Moderna Inc. (MRNA)
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
A big legal victory across the Atlantic Ocean was the news propelling Moderna (MRNA 15.94%) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during the trading session.
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism
Major U.S. equities indexes fluctuated on Wednesday before gaining momentum in the afternoon to close the session higher.
Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference
Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Moderna shares jump on insider stock purchases
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares moved higher after it was disclosed the company insiders have purchased $6 million in shares. According to filings with the Securities and Exchange Commission (SEC), CEO Stephane Bancel purchased 160,314 shares for $5 million.
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from billionaires to small retail investors -- have piled into some of the biggest winners. I'm talking about technology stocks, and, more specifically, players operating in the high-growth area of artificial intelligence (AI).
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.
Moderna's stock stumbles on report HHS is reviewing a $590 million bird-flu-vaccine award
The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (MRNA -6.67%) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine.
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.
Moderna (MRNA) International Revenue Performance Explored
Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
